aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

aTyr Pharma, Inc.NASDAQ: ATYR

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 98.04M shares rose 13.4% year over year, behind the +20.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +48.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +13.4% toward the trailing-twelve-month pace of +20.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
98.04M+0.0% QoQ
Last fiscal yearDec 2025
92.99M+25.2% YoY
LTMMar 2026
95.83M+20.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.4%——
1 year+25.2%——
3-year CAGR+48.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
92.99M USD
Year-over-year change
+25.2%
4-year CAGR
+48.6%

Weighted Avg Shares vs competitors

How ATYR compares with its peers on the latest reported figures

  • ATYR's LTM Mar 2026 weighted avg shares of 95.83M shares is the 2nd highest of the 8 companies compared; the peer median is 41.36M shares.
  • Its year-over-year change of +20.8% is the 6th highest of 8, against a peer median of +61.6%.
  • Over three fiscal years its annual growth of +48.5% compares with a peer median of +20.0%.
ATYR Competitors Peer median
Weighted Avg Shares for ATYR and competitors
Company Period LTM YoY 3-year CAGR
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026107.08M +1278.7%+372.5%
ATYRaTyr Pharma, Inc.LTM Mar 202695.83M +20.8%+48.5%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
HYFTMindWalk Holdings Corp.LTM Jan 202641.36M +43.8%+19.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
CAMPCAMP4 Therapeutics CorporationLTM Mar 202637.54M +102.0%—
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
Peer median (excluding ATYR) 41.36M+61.6%+20.0%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue010.39M353K235K190K
Cost of Revenue1.3M1.7M001.55M
Gross Profit(1.3M)8.69M353K235K(1.36M)
Gross Margin—83.7%100.0%100.0%-717.4%
Research & Development23.26M42.81M42.29M54.37M60.22M
Selling, General & Admin10.75M12.29M12.98M13.78M17.6M
Operating Expenses32.71M55.1M55.27M68.15M76.26M
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
EBITDA(32.47M)(43.65M)(47.66M)(62.48M)(72.57M)
EBITDA Margin—-420.3%-13500.3%-26588.1%-38192.1%
Operating Income(34.02M)(46.4M)(54.92M)(67.91M)(77.63M)
Operating Margin—-446.8%-15557.8%-28899.6%-40856.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses238K1.06M4.52M3.89M3.51M
Income Before Tax(33.78M)(45.34M)(50.4M)(64.02M)(74.12M)
Pre-Tax Margin—-436.6%-14276.8%-27243.4%-39009.5%
Income Tax Expense00000
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Net Margin—-436.5%-14274.5%-27243.8%-39009.5%
EPS (Basic)(1.77)(1.60)(0.94)(0.86)(0.80)
EPS (Diluted)(1.77)(1.60)(0.94)(0.86)(0.80)
Weighted Avg Shares19.08M28.42M53.61M74.26M92.99M
Weighted Avg Shares (Diluted)19.08M28.42M53.61M74.26M92.99M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.